Tirzepatide Injection
A dual GLP-1 and GIP receptor agonist that supports appetite regulation and weight management.
- Appetite regulation across two receptor pathways
- Weight management alongside protein, resistance training and monitoring
- Blood-sugar regulation
Indicative price · confirmed after eligibility · prescription treatment
What the second pathway actually adds
Most medications in this category act on one receptor pathway. Tirzepatide acts on two.
Whether that matters for you specifically is a clinical question rather than a marketing one — and we will not claim it is automatically better, because for some people it is not. But the second pathway is a real mechanistic difference, not a branding exercise, and it is worth understanding before you choose.
GLP-1 is the pathway most people have heard of. It is a hormone your gut releases after eating, and it does several things at once: signals fullness to the brain, slows how quickly the stomach empties, and helps regulate the insulin response to a meal. Medications acting here work with a system you already have rather than overriding it.
GIP is the second one, and it is less familiar. It is another gut hormone released after eating, and it is involved in insulin response and in how the body handles fat storage and energy use. Its role has been studied for decades but only became therapeutically interesting more recently.
Tirzepatide engages both. The reasoning is that appetite and metabolic regulation are not governed by a single switch, so acting on two complementary pathways may suit people whose response to a single-pathway approach has been limited.
What we will not tell you is how much more effective that makes it. We do not publish comparative outcome figures for compounded medications — the honest position is that the right choice is individual, and your clinician decides it with you based on your history, your response and your goals.
Tirzepatide acts on two receptor pathways, GLP-1 and GIP. The tirzepatide prescribed through ACT 2 Health is prepared by a licensed compounding pharmacy. It is not an FDA-approved product, and it is not the same as, equivalent to, or interchangeable with any branded medication.
How it works here
Every plan follows one path. Each step feeds the next. See the Medical Weight Loss approach.
- 01
Measure
We baseline your labs, history, and goals.
- 02
Plan
A clinician decides whether this fits — and what else might serve you.
- 03
Act
If appropriate, you start with clear guidance and high-touch support.
- 04
Track
We monitor how you respond on a defined cadence.
- 05
Adjust
Protocols are refined over time. Guided care, not a kit in the mail.
Tirzepatide or semaglutide?
The question everyone arrives with. The honest answer is that neither is “better” as a general matter.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Receptor pathways | Two — GLP-1 and GIP | One — GLP-1 |
| Track record in clinical use | Shorter | Longer |
| Route available here | Injection or oral capsule | Injection or oral capsule |
| Typical side-effect profile | Mostly gastrointestinal | Mostly gastrointestinal |
| Cost position at ACT 2 | Higher | Lower |
| Often considered when | A single-pathway approach has not produced the response hoped for, or a dual-pathway approach fits the metabolic picture | Starting out, or where the longer track record is reassuring |
| Available at ACT 2 | Yes | Yes |
Scroll the table sideways to compare →
The honest summary: this is a clinical decision, not a ranking. The two act on a different number of receptor pathways, the side-effect profiles overlap substantially, and individual response varies more than the difference between the molecules. Your provider decides with you.
Who it is for — and the cutoff we do not use
Tirzepatide is considered for adults in midlife seeking medical weight management, particularly where a dual-pathway option fits the picture.
There is no blanket BMI cutoff here. Eligibility is assessed case by case, on your symptoms, your metabolic picture and your history — not on a single number that automatically qualifies or disqualifies you. That matters more in this age group than people expect, because midlife weight change is frequently entangled with hormonal shifts, sleep, medication effects and thyroid function, and a BMI threshold captures none of that.
Which is also why we measure first. Sometimes the more useful finding is that something else is driving it.
The thing that matters most after 45: protecting muscle
This is where weight management in midlife genuinely differs from weight management at 30, and it is the part most GLP-1 marketing skips.
Any significant weight loss costs you some lean mass alongside fat. That is true of every method, not just medication. But muscle mass and bone density are already declining with age, and losing weight quickly without protecting them can leave you lighter, weaker and more fragile — a worse outcome than the number on the scale suggests.
So the protocol matters as much as the medication.
Protein intake goes up, not down, during weight loss.
Resistance training is not optional. It is the single most effective protective measure available, and walking does not substitute for it.
Monitoring tracks body composition, not just weight — because weight alone cannot tell you what you lost.
Rate matters. Faster is not better if more of what is leaving is muscle.
If a provider puts you on a GLP-1 without discussing any of this, they are managing your weight and ignoring your health. It is the same distinction that separates a program from a prescription.
What to expect, and what to watch for
Side effects are mostly gastrointestinal — nausea most commonly, along with digestive changes. These often ease over time and with careful adjustment by your clinician. They are the most common reason a plan gets modified.
Contact your clinician promptly for: severe or persistent abdominal pain, which can indicate pancreatitis or a gallbladder problem; persistent vomiting or signs of dehydration; or a lump or swelling in the neck, difficulty swallowing, or persistent hoarseness.
Not appropriate if you have a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; if you are pregnant, breastfeeding or trying to conceive; or with a history of pancreatitis without careful evaluation. Gallbladder disease, significant kidney impairment and certain gastrointestinal conditions all need review first.
Tell your clinician about every medication you take. Because these medications slow stomach emptying, absorption of other things you take can change — and that includes oral contraceptives.
What happens if you stop
Worth understanding before you start rather than after.
These medications work while you are taking them. Appetite regulation generally returns toward its previous state when you stop, and for many people weight follows. That is not a failure of willpower or a flaw in the medication — it is how the mechanism works.
What changes the outcome is what you built while you were on it. The eating patterns, the training habit, the sleep and the muscle you protected are what carry forward. Which is the honest argument for treating this as a program with a plan for afterwards, rather than a prescription with an open end.
Your protocol is reviewed and adjusted over time, and some members taper as habits and biomarkers improve.
Delivery
A once-weekly subcutaneous injection, with your regimen guided by your clinician over time.
Is it right for you?
Adults 45+ seeking medical weight management, especially where a dual-pathway option fits the picture — and who want monitoring rather than a monthly delivery. See medical weight loss for how the program is run.
If tirzepatide is not the right fit
If needles are the obstacle, oral tirzepatide is the same molecule by a different route. If you would prefer the longer track record, semaglutide. If insulin resistance is central to your picture, metformin may belong in the conversation, and a CGM can make the metabolic response visible rather than inferred.
If your insurance already covers a branded GLP-1, the Weight Loss Program Membership may be the better structure: you obtain the branded medication through your own pharmacy benefit and pay us only for the clinical care around it. Worth checking before you commit, because the price shown here is an ongoing monthly cost plus periodic labs, not a one-off.
And if you are a woman in perimenopause or menopause, it is worth reading hormone therapy alongside this. Midlife weight change and hormonal change are frequently entangled, and treating one while ignoring the other is a common way to get a disappointing result.
Often considered alongside
Semaglutide Injection
CompoundedA GLP-1 receptor agonist that works with your body's appetite and blood-sugar signaling to support weight management.
View treatmentTirzepatide Oral Capsules
CompoundedA needle-free oral form of tirzepatide, acting on the GLP-1 and GIP pathways.
View treatmentWeight Loss Program Membership
Monthly clinical oversight and plan adjustment for members using branded GLP-1 medications.
View treatmentProducts marked Compounded are prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved and are not equivalent to or interchangeable with any branded product.
What we will not claim
This page quotes no trial percentages and makes no comparative efficacy claim, and that is deliberate. Published trial results belong to the FDA-approved branded product they were generated with; carrying them across to a compounded preparation would be a misstatement rather than a shortcut. What we can tell you is this: tirzepatide is prescribed only for eligible patients under clinical evaluation and ongoing monitoring, side effects are mostly gastrointestinal and often ease over time, and individual response varies more than the difference between one molecule and another.
References
Government and professional-society sources consulted for this page.
- Tirzepatide Injection — MedlinePlus (U.S. National Library of Medicine)
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration
Frequently asked questions
Neither is “better” as a general matter. The two act on different numbers of receptor pathways, and the right choice is individual. Your provider decides with you. We do not publish comparative outcome figures for compounded medications.
GIP is a gut hormone released after eating, involved in insulin response and in how the body handles fat storage and energy use. Tirzepatide engages it alongside GLP-1. The reasoning is that appetite and metabolic regulation are not governed by one switch — but whether the second pathway benefits you specifically is a clinical judgment.
No. There is no blanket BMI cutoff. Eligibility is assessed case by case on your symptoms, metabolic picture and history — which matters in midlife, where weight change is often entangled with hormones, sleep and thyroid function.
Some muscle loss can occur with any significant weight loss. Our protocols emphasize protein, resistance training and ongoing monitoring to support lean mass. Individual results vary. This matters more after 45 than at 30, because lean mass is already declining with age.
As a once-weekly injection, with your regimen guided and adjusted by your clinician.
Mostly gastrointestinal — nausea most commonly, along with digestive changes. These often ease with time and careful adjustment. Contact your clinician promptly for severe abdominal pain, persistent vomiting, or any neck lump, swallowing difficulty or persistent hoarseness.
Anyone with a personal or family history of medullary thyroid carcinoma or MEN2; anyone pregnant, breastfeeding or trying to conceive; and anyone with a history of pancreatitis without careful evaluation. Gallbladder disease, kidney impairment and certain GI conditions need review first.
Appetite regulation generally returns toward its previous state when you stop, and for many people weight follows. What carries forward is what you built while on it — the habits, the training and the muscle you protected. That is why the plan for afterwards matters as much as the plan for now.
Not necessarily. Your protocol is reviewed and adjusted over time, and some members taper as habits and biomarkers improve.
It can. Because these medications slow stomach emptying, the absorption of other things you take can change — including oral contraceptives. Bring your full medication list to your evaluation.
See if Tirzepatide Injection fits your plan
The right plan begins with knowing where you are. Start with a short eligibility check and a baseline — and we'll tell you, honestly, what fits.
We measure first. Then we act.
ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.